LOGIN  |  REGISTER
Chimerix
Viking Therapeutics

MultiPlan Announces Participation at Upcoming Conferences

May 12, 2023 | Last Trade: US$6.45 1.24 23.80

NEW YORK / May 12, 2023 / Business Wire / MultiPlan Corporation (NYSE:MPLN) (“MultiPlan” or the “Company”), a leading provider of technology and data-enabled end-to-end cost management, payment and revenue integrity solutions to the U.S. healthcare industry, today announced that members of its management team will participate in person at the following conferences in May and June 2023:

  • Goldman Sachs Eighth Annual Leverage and Credit Conference – Tuesday, May 23, 2023 at the Terranea Resort – Rancho Palos Verdes, CA
  • Goldman Sachs 44th Global Healthcare Conference – Wednesday, June 14, 2023 at the Waldorf Astoria Monarch Beach Resort – Dana Point, CA

A live webcast and audio archive of the events, if available, may be accessed through the investor relations section of MultiPlan’s website at investors.multiplan.us/events-and-presentations.

About MultiPlan

MultiPlan is committed to delivering affordability, efficiency and fairness to the US healthcare system by helping healthcare payors manage the cost of care, improve their competitiveness and inspire positive change. Leveraging sophisticated technology, data analytics and a team rich with industry experience, MultiPlan interprets customers’ needs and customizes innovative solutions that combine its payment and revenue integrity, network-based and analytics-based services. MultiPlan is a trusted partner to over 700 healthcare payors in the commercial health, government and property and casualty markets. For more information, visit multiplan.com.

Viking Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB